SCHEMBL13633895

SCHEMBL13633895

CCc1nc(-c2ccc(Cl)s2)oc1C

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.44
ALDH1A1 P00352 6/20 0.43
HPGD P15428 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
UTRN P46939 1/20 0.42
LMNA P02545 3/20 0.41
GAA P10253 1/20 0.41
PTGS1 P23219 3/20 0.39
PTGS2 P35354 3/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HTR2A P28223 1/20 0.37
PPARG P37231 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
KDM1A O60341 1/20 0.36
PDE4B Q07343 1/20 0.35
PDE4D Q08499 1/20 0.35
PPARA Q07869 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13633776 0.85 ALDH1A1 (0.54) KDM4EALDH1A1LMNAGAAPTGS1
SCHEMBL13633902 0.81 ALDH1A1 (0.42) KDM4EALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL13633784 0.80 ALDH1A1 (0.43) KDM4EALDH1A1HPGDSMN1; SMN2UTRN
SCHEMBL13633891 0.79 PPARG (0.52) KDM4EALDH1A1HPGDLMNAGAA
SCHEMBL5476168 0.74 ALDH1A1 (0.53) KDM4EALDH1A1LMNAGAAPTGS1
SCHEMBL13633793 0.73 KDM4E (0.54) KDM4EALDH1A1HPGDSMN1; SMN2LMNA
Hydrochloric Acid SCHEMBL2819349 0.73 CYP2A6 (0.55) KDM4EALDH1A1SMN1; SMN2LMNANPSR1
SCHEMBL13179907 0.72 HSD17B10 (0.58) KDM4EALDH1A1HPGDSMN1; SMN2LMNA
SCHEMBL13633788 0.72 IKBKB (0.47) KDM4EALDH1A1MEN1KMT2AHTR2A
SCHEMBL14439025 0.71 ALDH1A1 (0.53) KDM4EALDH1A1LMNAGAAPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275565-A1 Substituted aralkyl derivatives CADILA HEALTHCARE LIMITED (IN) 2009-11-05 US disclosed
US-20090275565-A1 Substituted aralkyl derivatives CADILA HEALTHCARE LIMITED (IN) 2009-11-05 US disclosed
EP-1569916-B1 SUBSTITUTED ARALKYL DERIVATIVES CADILA HEALTHCARE LTD (IN) 2009-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275565-A1 Substituted aralkyl derivatives UGT1A7, UGT1A10, UGT2B7 KDM4E 4614/4885ALDH1A1 1255/4885HPGD 2962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.